πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,413 results for β€œACE” Clear

  1. BI 764198, Placebo to match BI 764198, BI 764198, BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 2 small molecule active

    1 trial

  2. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

  3. BION-1301 Single Dose

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 2 small molecule active

    1 trial

  4. BIS-001ER

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Impaired Awareness Seizures

    phase 2 small molecule active

    1 trial

  5. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  7. BMN 044 IV 6 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  8. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    MPS IV A

    phase 2 small molecule terminated

    2 trials

  9. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IVA

    phase 2 small molecule terminated

    3 trials

  10. BMN 165 (rAvPAL-PEG)

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 mab completed

    1 trial

  11. BMN 190

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    2 trials

  12. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial

  13. BMN 307

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 2 small molecule active

    1 trial

  14. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  15. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  16. BMN 701

    BioMarin Pharmaceutical Australia Pty Ltd

    Pompe Disease

    phase 2 mab completed

    2 trials

  17. BMS-945429 Placebo

    CSL Behring GmbH

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  18. BRENSOCATIB, MOMETASONE , BRENSOCATIB, The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP.

    Insmed Limited

    Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

    phase 2 small molecule active

    1 trial

  19. BRONCHO-VAXOM Children Capsules placebo, BRONCHO-VAXOM, 3,5mg, kapsuΕ‚ki

    Lacuna Pharma Pty Ltd

    Recurrent wheezing

    phase 2 small molecule active

    1 trial

  20. BUL02, Placebo orodispersible tablets, BUL03

    Dr. Falk Pharma GmbH

    Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection

    phase 2 small molecule active

    1 trial

  21. BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  22. BYL719, BYL719, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  23. Bactrim 160 mg + 800 mg compresse, CHLORPHENAMINE MALEATE, ALLOPURINOL, BRUKINSA 80 mg hard capsules, DEXAMETHASONE PHOSPHATE, VENETOCLAX, VENETOCLAX, Gazyvaro 1,000 mg concentrate for solution for infusion., Lamivudina Mylan 150 mg compresse rivestite con film, VENETOCLAX, PARACETAMOL

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  24. Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

    AstraZeneca

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources